...
swtx-img

SpringWorks Therapeutics Inc, Common Stock

SWTX

NSQ

$38.3

-$0.39

(-1.01%)

1D
Industry: Biotechnology Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$2.96B
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
1.05M
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
0.79
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$28.21 L
$53.92 H
$38.3

About SpringWorks Therapeutics Inc, Common Stock

SpringWorks Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is OGSIVEO (nirogacestat), an oral small molecule gamma secretase inhibitor that is in Phase III DeFi trial for the treatment of desmoid tumors; and Nirogacestat, is also in Phase 2 clinical development as a monotherapy for the treatment of ovarian granulosa cell tumors (GCT), a subtype of ovarian cancer. The company is also involved in the development of mirdametinib, an oral small molecule MEK inhibitor that is in Phase 2b clinical trials for the treatment of neurofibromatosis type 1-associated plexiform neurofibromas (NF1-PN); mirdametinib + lifirafenib, a combination therapy that is in Phase 1b clinical trial in patients with advanced or refractory solid tumors; and mirdametinib in monotherapy and combination approaches to treat other genetically defined solid tumors, including Phase 1/2 clinical trial for the treatment of pediatric and young adult patients with low-grade gliomas. In addition, it develops Brimarafenib (BGB-3245), an oral selective small molecule inhibitor of monomeric and dimeric forms of activating BRAF mutations. The company has collaborations with BeiGene, Ltd. and GlaxoSmithKline LLC; and license agreements with Pfizer Inc. for nirogacestat and mirdametinib. It also has a license agreement with Katholieke Universiteit Leuven and the Flanders Institute for Biotechnology for a portfolio of novel small molecule inhibitors of the TEA Domain; and Dana-Farber Cancer Institute for a portfolio of novel small molecule inhibitors of Epidermal Growth Factor Receptor. The company was founded in 2017 and is headquartered in Stamford, Connecticut. more

Industry: BiotechnologySector: Health Care

Returns

Time FrameSWTXSectorS&P500
1-Week Return-7.84%-2.27%-0.57%
1-Month Return10.34%-3.96%1.21%
3-Month Return2.35%-9.7%7.57%
6-Month Return-2.15%-3.37%11.45%
1-Year Return10.82%3.71%28.48%
3-Year Return-45.3%3.8%29.52%
5-Year Return32.53%39.78%90.66%
10-Year Return69.24%106.91%203.75%

Financials

Dec '19Dec '20Dec '21Dec '22Dec '235YR TREND
Total Revenue-35.00M35.00M6.15M5.45M[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":17.56,"profit":true},{"date":"2023-12-31","value":15.56,"profit":true}]
Cost of Revenue192.00K349.00K490.00K1.90M422.00K[{"date":"2019-12-31","value":10.13,"profit":true},{"date":"2020-12-31","value":18.41,"profit":true},{"date":"2021-12-31","value":25.84,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":22.26,"profit":true}]
Gross Profit(192.00K)34.65M(490.00K)6.15M5.03M[{"date":"2019-12-31","value":-0.55,"profit":false},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":-1.41,"profit":false},{"date":"2022-12-31","value":17.74,"profit":true},{"date":"2023-12-31","value":14.5,"profit":true}]
Gross Margin-99.00%(1.40%)100.00%92.25%[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":99,"profit":true},{"date":"2021-12-31","value":-1.4,"profit":false},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":92.25,"profit":true}]
Operating Expenses59.24M81.32M173.47M280.67M348.04M[{"date":"2019-12-31","value":17.02,"profit":true},{"date":"2020-12-31","value":23.37,"profit":true},{"date":"2021-12-31","value":49.84,"profit":true},{"date":"2022-12-31","value":80.64,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Operating Income(59.24M)(46.32M)(173.47M)(280.67M)(343.01M)[{"date":"2019-12-31","value":-5923900000,"profit":false},{"date":"2020-12-31","value":-4632400000,"profit":false},{"date":"2021-12-31","value":-17346800000,"profit":false},{"date":"2022-12-31","value":-28067400000,"profit":false},{"date":"2023-12-31","value":-34301300000,"profit":false}]
Total Non-Operating Income/Expense4.48M2.08M256.00K9.54M40.06M[{"date":"2019-12-31","value":11.18,"profit":true},{"date":"2020-12-31","value":5.19,"profit":true},{"date":"2021-12-31","value":0.64,"profit":true},{"date":"2022-12-31","value":23.82,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Pre-Tax Income(58.31M)(45.57M)(173.91M)(277.42M)(325.10M)[{"date":"2019-12-31","value":-5830600000,"profit":false},{"date":"2020-12-31","value":-4557400000,"profit":false},{"date":"2021-12-31","value":-17391000000,"profit":false},{"date":"2022-12-31","value":-27741700000,"profit":false},{"date":"2023-12-31","value":-32510400000,"profit":false}]
Income Taxes(3.55M)(1.33M)(698.00K)(3.26M)(22.95M)[{"date":"2019-12-31","value":-354700000,"profit":false},{"date":"2020-12-31","value":-133000000,"profit":false},{"date":"2021-12-31","value":-69800000,"profit":false},{"date":"2022-12-31","value":-325700000,"profit":false},{"date":"2023-12-31","value":-2294700000,"profit":false}]
Income After Taxes(54.76M)(44.24M)(173.21M)(274.16M)(302.16M)[{"date":"2019-12-31","value":-5475900000,"profit":false},{"date":"2020-12-31","value":-4424400000,"profit":false},{"date":"2021-12-31","value":-17321200000,"profit":false},{"date":"2022-12-31","value":-27416000000,"profit":false},{"date":"2023-12-31","value":-30215700000,"profit":false}]
Income From Continuous Operations(58.31M)(45.57M)(173.91M)(277.42M)(304.96M)[{"date":"2019-12-31","value":-5830600000,"profit":false},{"date":"2020-12-31","value":-4557400000,"profit":false},{"date":"2021-12-31","value":-17391000000,"profit":false},{"date":"2022-12-31","value":-27741700000,"profit":false},{"date":"2023-12-31","value":-30496000000,"profit":false}]
Income From Discontinued Operations-----[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Net Income(54.76M)(44.24M)(173.21M)(274.16M)(325.10M)[{"date":"2019-12-31","value":-5475900000,"profit":false},{"date":"2020-12-31","value":-4424400000,"profit":false},{"date":"2021-12-31","value":-17321200000,"profit":false},{"date":"2022-12-31","value":-27416000000,"profit":false},{"date":"2023-12-31","value":-32510400000,"profit":false}]
EPS (Diluted)(2.59)(1.05)(3.58)(5.21)(5.15)[{"date":"2019-12-31","value":-259,"profit":false},{"date":"2020-12-31","value":-105,"profit":false},{"date":"2021-12-31","value":-358,"profit":false},{"date":"2022-12-31","value":-521,"profit":false},{"date":"2023-12-31","value":-515,"profit":false}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

SWTX
Cash Ratio 5.33
Current Ratio 6.16
Quick Ratio 6.02

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

SWTX
ROA (LTM) -34.28%
ROE (LTM) -59.33%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

SWTX
Debt Ratio Lower is generally better. Negative is bad. 0.13
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.87

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

SWTX
Trailing PE NM
Forward PE 322.58
P/S (TTM) 21.82
P/B 5.55
Price/FCF NM
EV/R 19.10
EV/Ebitda NM

FAQs

What is SpringWorks Therapeutics Inc share price today?

SpringWorks Therapeutics Inc (SWTX) share price today is $38.3

Can Indians buy SpringWorks Therapeutics Inc shares?

Yes, Indians can buy shares of SpringWorks Therapeutics Inc (SWTX) on Vested. To buy SpringWorks Therapeutics Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in SWTX stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of SpringWorks Therapeutics Inc be purchased?

Yes, you can purchase fractional shares of SpringWorks Therapeutics Inc (SWTX) via the Vested app. You can start investing in SpringWorks Therapeutics Inc (SWTX) with a minimum investment of $1.

How to invest in SpringWorks Therapeutics Inc shares from India?

You can invest in shares of SpringWorks Therapeutics Inc (SWTX) via Vested in three simple steps:

  • Click on Sign Up or Invest in SWTX stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in SpringWorks Therapeutics Inc shares
What is SpringWorks Therapeutics Inc 52-week high and low stock price?

The 52-week high price of SpringWorks Therapeutics Inc (SWTX) is $53.92. The 52-week low price of SpringWorks Therapeutics Inc (SWTX) is $28.21.

What is SpringWorks Therapeutics Inc price-to-earnings (P/E) ratio?

The price-to-earnings (P/E) ratio of SpringWorks Therapeutics Inc (SWTX) is

What is SpringWorks Therapeutics Inc price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of SpringWorks Therapeutics Inc (SWTX) is 5.55

What is SpringWorks Therapeutics Inc dividend yield?

The dividend yield of SpringWorks Therapeutics Inc (SWTX) is 0.00%

What is the Market Cap of SpringWorks Therapeutics Inc?

The market capitalization of SpringWorks Therapeutics Inc (SWTX) is $2.96B

What is SpringWorks Therapeutics Inc’s stock symbol?

The stock symbol (or ticker) of SpringWorks Therapeutics Inc is SWTX

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top